The supplement aisle promises gut healing, recovery, immunity. The trials are tighter than that: a strong result if you have post-infection IBS that won't quit, a smaller real one for endurance athletes finishing long runs in the heat, and a modest postprandial glucose effect at meal-sized doses. For everyone else, the daily 5-g habit is doing about what 5 g of any unflavoured powder would do — which is nothing. Cheap to try, easy to take, easy to skip.
Glutamine is the most common amino acid floating in your blood, and the one your muscles stockpile most — your body already makes 10 to 25 grams of it a day on its own, mostly out of skeletal muscle Cruzat et al. 2018. The reason supplement makers care about it: two specific tissues burn it faster than they burn sugar. The cells lining your small intestine, and your immune cells — lymphocytes, the white blood cells that fight infections — both use glutamine as a primary fuel.
That's the whole pitch in one sentence: feed the gut wall, feed the immune system. The catch is that for a healthy person eating normally, those tissues already have all the glutamine they want. The supplement only matters when the supply chain breaks — a stomach infection that damaged the lining, an ultramarathon that ran the tank dry, a serious burn, or a population with a specific metabolic problem.
When supply does break, the lab work is clear: glutamine puts the proteins that hold the gut lining together — the seals between cells, called tight junctions — back where they belong Wang et al. 2015. That's the mechanism behind the "leaky gut" claim. It's also where the gap between mechanism and human results opens up.
What the trials actually say
Pool every controlled trial of glutamine on gut permeability — every "leaky gut" study — and the overall effect is nothing. A 2024 meta-analysis ran the numbers across ten trials and found no significant change at the population level Singleton et al. 2024. The only doses that moved the needle were above 30 grams a day for less than two weeks. The "scoop in your morning coffee, every day, forever" pattern most people run is well below the floor of doses that have ever done anything in a trial.
That said, three trials are worth taking seriously, because each names a population this works for.
Two other live use cases sit outside the supplement-aisle conversation but anchor the substance's serious profile. The FDA approved a pharmaceutical-grade L-glutamine — same molecule, prescription-only — in 2017 for sickle cell disease, on the back of a Phase 3 trial that cut yearly pain crises and hospitalisations FDA 2017 Niihara et al. 2018. And in hospital, for people with serious burns covering more than a fifth of the body, the European clinical-nutrition guideline recommends 0.3 to 0.5 g/kg per day for the first ten to fifteen days Singer et al. 2023. Neither is a supplement-shelf decision; both confirm that the molecule does real things when the body's demand for it is genuinely outrunning the supply.
The headline claims the supplement industry sells hardest — bigger muscles, faster recovery, fewer everyday illnesses — are the ones the trials have nulled most cleanly. A 2019 meta-analysis pooling glutamine trials in trained athletes found no effect on strength, no effect on body composition, and no convincing effect on routine immune function Ramezani Ahmadi et al. 2019. The most that gets through replication is a small reduction in muscle soreness Legault et al. 2015. If you came for muscle, the data says go take creatine.
What you're actually deciding
The stakes for the average reader are mostly about money and attention, not health. Twenty-five dollars a month on a supplement that does nothing isn't going to hurt you — but it does buy a small confidence trick. Each month it sits on the counter, the reader thinks they're doing something about a problem they may not actually have. The fibre target they're missing, the food sensitivity they haven't worked up, the sleep they're cutting short — those move the same gut symptoms the supplement is promising to fix, and they move them at real effect sizes. The trade is the bandwidth.
For the marathon runner finishing long efforts with stomach cramps, or the person whose gut has been off since a stomach bug two years ago and hasn't come back: skipping this is a missed cheap intervention. The trial-grade dose, in the trial-grade population, has one of the largest published effects in the IBS literature.
If you do take it, take the trial dose
The supplement aisle's default suggestion — five grams in water once a day, every day, forever — is the dose nothing was tested at. The protocols that produced the published effects are higher, more specific, and time-limited.
Take it on an empty-ish stomach, with water; food competes for the same gut absorption. The bigger doses can cause bloating or loose stools — split them rather than dose them as a single 15 g hit.
When not to take it
The myths the supplement aisle leans on
"Leaky gut, take glutamine." This is the dominant pitch and it is mostly wrong as written. The combined trials in mixed populations show no effect at consumer doses; the cases where glutamine moves gut permeability are people with a specific, measurable barrier defect (a stomach infection that damaged the lining; the kind of permeability the lab sees after a hard run) at doses considerably higher than what's on the back of the tub Singleton et al. 2024. For a healthy reader with normal digestion, the daily scoop isn't doing what the bottle says it does.
"More glutamine, more muscle." The bodybuilding-magazine claim that won't die. Your muscles already make 10 to 25 grams of glutamine a day on their own; adding a few more grams from a tub doesn't move strength, doesn't move muscle size, and doesn't move recovery in any meaningful way that meta-analyses can find Ramezani Ahmadi et al. 2019. If muscle is the goal, the molecule that actually works at the price of a coffee is creatine.
"Plasma glutamine drops after hard exercise, so we need to top it up." The popular form of this argument doesn't hold up — the levels at which lymphocyte function actually suffers in the lab are far below where post-exercise blood drops to. The narrow win that has survived replication is the post-race cold rate after very long efforts, dosed right after the race; not a general "drink your glutamine, never get sick" effect Cruzat et al. 2018.
"It's just an amino acid, so more is always safer." True at supplement doses. False in the hospital — the ICU trials are a real harm signal in real patients Heyland et al. 2013. The lesson isn't that 5 g is dangerous, it's that "natural" doesn't mean "infinitely scalable".
What changes if you actually fit one of the use cases
For the person whose gut hasn't been right since a stomach bug — the one whose Friday plans hinge on knowing where the bathroom is, who's been carrying anti-diarrhoea pills around like a talisman — the trial gives a real number. About four out of five people in the Zhou study hit a meaningful symptom drop by the end of eight weeks, and the lab markers of a leaky barrier returned to normal Zhou et al. 2019. The version of you that books the road trip without scouting the rest stops, that takes the bathroom-trip math out of every social calendar — that's what's on the table. Eight weeks. Either it lands or it doesn't.
For the marathoner: not race-changing. The trial-grade pre-race dose blunts the gut leak that turns the second half of long efforts into a cramping mess, and the post-race dose buys back roughly a coin-flip's worth of the cold-or-sore-throat rate in the week that follows Castell et al. 1996. Small wins, but for someone training through a hot summer, real.
For the type 2 diabetic experimenting with adjuncts: the postprandial number is honest — about a 10% reduction in the after-meal glucose spike at 30 g taken with the meal Samocha-Bonet et al. 2011. Not a substitute for your medication; an additional, cheap knob.
For everyone else — the average reader who picked up the tub because Instagram said gut health — there's nothing on the table. The dream payoff supplement marketing implies, of a healed gut and a new immune system, was never in the trial data to begin with. The realistic payoff for skipping it is the $25 a month, the counter space, and the chance to spend the same attention on something with a real effect size: more fibre, more sleep, fewer ultra-processed meals, and — if symptoms are genuine and persistent — a workup with a gastroenterologist rather than a supplement.
If your gut symptoms are real, don't stop at glutamine
Persistent loose stools, urgency, or bloating that doesn't track with anything obvious deserves a workup, not a supplement. Worth knowing exists, in roughly the order most people benefit from working through them:
- Celiac screening — a blood test, before you cut gluten on your own, which makes the test useless.
- SIBO (small-intestinal bacterial overgrowth) — a breath test if symptoms point that way.
- The low-FODMAP diet as a structured trial — works in about three-quarters of IBS patients when run properly.
- Soluble fibre at 30 g a day from real food (or psyllium if food is hard) — the cheapest and best-evidenced gut intervention there is.
- Creatine, if you came to glutamine looking for muscle and recovery — different molecule, real effects, similar price.
Substance + claimed effects
L-glutamine is a non-essential, conditionally essential amino acid: the most abundant free amino acid in human plasma (~600–700 µmol/L) and the dominant species in the skeletal-muscle intracellular free-amino-acid pool (~60% of the non-taurine pool, on the order of 20 mmol/L) Cruzat et al. 2018. Endogenous synthesis (~10–25 g/day, primarily in skeletal muscle via glutamine synthetase) covers normal needs; supplementation only matters when demand exceeds supply, which happens in catabolic stress (trauma, sepsis, burns, very prolonged exercise) and when a metabolically demanding tissue (enterocytes, lymphocytes) loses its preferred fuel Cruzat et al. 2018. Sold as a free-form powder (5–10 g per dose, $20–40 for a multi-month supply) for "gut healing" and "recovery". The entry covers the four named consequences in the brief — intestinal barrier integrity, immune function, post-exercise recovery, glucose handling — plus an honest treatment of where the supplement consistently underperforms versus where it has earned its niche (post-infectious IBS, sickle-cell pain crises, endurance-athlete gut leak, severe burns/parenteral nutrition).
Evidence by addressing question
mechanism
Enterocyte fuel. Small-bowel epithelial cells (enterocytes) and immune cells (lymphocytes, macrophages, neutrophils) use glutamine at rates comparable to or greater than glucose Cruzat et al. 2018. The gut extracts a substantial fraction of dietary and arterial glutamine on first pass — splanchnic uptake is so high that oral glutamine raises gut tissue concentrations far more than it raises peripheral plasma. This is why oral dosing targets gut more efficiently than it targets muscle.
Tight junctions. In Caco-2 monolayers, porcine jejunal epithelium, and rodent stress models, glutamine deprivation collapses expression of the tight-junction proteins claudin-1, claudin-4, occludin, and ZO-1/2; restoring glutamine restores them, with proposed signalling through CaMK kinase 2 → AMPK and through HSP70/mTOR Wang et al. 2015. The translational claim — that this protects the barrier in humans under physiologic stress — is supported in narrow conditions (heat-exercise, post-infectious IBS) but does not generalise.
Immune cell metabolism. Glutamine is essential substrate for lymphocyte proliferation, cytokine synthesis, macrophage phagocytic activity, and neutrophil bacterial killing Cruzat et al. 2018. Plasma glutamine falls after prolonged exercise; Newsholme and Castell hypothesised that this fall causes the post-exercise "open window" of infection susceptibility Castell et al. 1996. The hypothesis turned out to overstate causality (in-vitro glutamine concentrations needed to limit lymphocyte function are far below the post-exercise nadir) but the link between supplementation and reduced URTI rates has survived in narrower form.
GLP-1 secretion. Oral glutamine triggers L-cell release of GLP-1 (and glucagon, and insulin) more strongly than equivalent doses of other amino acids in healthy, obese, and type-2 diabetic subjects — the substrate-induced incretin effect Greenfield et al. 2009. This is the mechanism behind glutamine's modest postprandial glucose-lowering effect, not an insulin-sensitising effect at the muscle.
evidence
Gut permeability — pooled. A 2024 systematic review and meta-analysis of 10 RCTs (n=352) found no overall effect of glutamine on intestinal permeability across all populations and doses pooled. The signal appeared only in subgroup analysis: doses above ~30 g/day for less than two weeks reduced permeability; lower-dose chronic protocols did not Singleton et al. 2024. This is the most important honest framing of the gut-barrier literature: there is a real effect, but it requires a much higher dose, in a stressed barrier, on a much shorter timeline, than the "5 g of glutamine in my morning shake forever" pattern most consumers run.
Post-infectious IBS-D. The cleanest positive trial: 106 adults with post-infectious diarrhoea-predominant IBS and documented increased intestinal permeability (Rome III IBS-D, lactulose/mannitol elevated) randomised to 5 g three-times-daily L-glutamine (15 g/day) vs maltodextrin placebo for 8 weeks. The glutamine arm achieved the primary endpoint (≥50-point IBS-SS reduction) at 79.6% vs 5.8% for placebo, with normalisation of lactulose/mannitol ratio Zhou et al. 2019. Effect size is unusually large for an IBS trial; the population was tightly selected (post-infectious, permeability-elevated subset), so generalisability beyond that phenotype is unproven.
Exercise-induced gut leak. Zuhl et al. 2014 randomised 8 runners to glutamine (0.9 g/kg fat-free mass for 7 days) or placebo before a 60-min treadmill run; lactulose/rhamnose permeability ratio was elevated by exercise on placebo and held at baseline on glutamine, with parallel upregulation of intestinal claudin-1 in biopsied tissue Zuhl et al. 2014. Pugh et al. 2017 ran a dose-response in 10 athletes (0, 0.25, 0.5, 0.9 g/kg) running in the heat — a clear dose-dependent attenuation of permeability, with effects beginning at 0.25 g/kg (~17 g for a 70-kg athlete) taken 2 h before exercise Pugh et al. 2017. Both are small mechanistic studies; clinical-symptom endpoints (GI distress, performance) less consistently replicate.
Upper-respiratory infection in endurance athletes. Castell et al. 1996 — the still-cited foundational result — pooled marathon and ultra-marathon runners (n=151) drinking 5 g glutamine vs placebo immediately and 2 h after the race. Self-reported URTI in the week following the race: 19% on glutamine vs 51% on placebo Castell et al. 1996. Replication has been mixed; a 2019 meta-analysis of glutamine in athletes found no convincing effect on performance or body composition, with the immune-function signal limited to post-endurance specifically Ramezani Ahmadi et al. 2019. The original effect probably reflects a real but narrow window: very prolonged exercise + immediate post-event dosing.
Critical care — the harm signal. The REDOXS trial (n=1223 ICU patients with multi-organ failure on mechanical ventilation) randomised early high-dose glutamine (0.35 g/kg/day IV + 30 g/day enteral, started within 24 h) vs placebo in a 2×2 factorial with antioxidants. 28-day mortality was no different, but in-hospital mortality (32.4% vs 27.2%) and 6-month mortality were higher on glutamine — a clear harm signal, concentrated in patients with renal failure at enrollment Heyland et al. 2013. RE-ENERGIZE (n=1200, severe burns ≥20% body surface area, 0.5 g/kg/day enteral glutamine for ≥7 days) found no benefit on time to discharge alive, 6-month mortality, length of stay, or bacteraemia — and post hoc no harm Heyland et al. 2022. ESPEN's 2023 ICU guideline reflects the resulting caution: parenteral glutamine only in patients on exclusive parenteral nutrition, enteral glutamine 0.3–0.5 g/kg/day specifically in major burns for 10–15 days; not routine Singer et al. 2023.
Post-exercise muscle recovery. Legault et al. 2015: 8 men, eccentric knee-extension protocol, 0.3 g/kg L-glutamine four times daily vs placebo for 72 h. Strength recovery was modestly accelerated at 48 h and 72 h on glutamine; soreness ratings lower in men. Small, single-centre Legault et al. 2015. The Ramezani-Ahmadi meta-analysis confirms the pattern: a small attenuation of soreness with no measurable effect on muscle-damage biomarkers (CK, LDH), no effect on strength or hypertrophy in chronic protocols Ramezani Ahmadi et al. 2019. As a muscle-building or strength-recovery supplement, glutamine is essentially inert.
Glucose handling. Greenfield et al. 2009 gave 30 g oral glutamine to lean, obese, and T2D subjects; glutamine raised GLP-1, insulin, and glucagon dose-dependently in all groups Greenfield et al. 2009. Samocha-Bonet et al. 2011 then showed that adding 30 g glutamine to a standard meal in T2D patients reduced 3-h postprandial glucose AUC by ~10% and augmented active GLP-1 — a real but modest effect, well below what GLP-1 agonist drugs achieve Samocha-Bonet et al. 2011. Longer trials (4–6 weeks) showed weaker/inconsistent fasting-glucose and HbA1c effects; the postprandial signal is the robust one.
Sickle-cell disease. Tangential to the brief but relevant context: the Phase 3 Niihara trial of pharmaceutical-grade L-glutamine (0.3 g/kg twice daily, oral) in 230 sickle-cell patients reduced median sickle-cell pain crises from 3 to 3 (intervention) vs 4 (placebo), hospitalisations from 3 to 2, and hospital days Niihara et al. 2018. FDA-approved as Endari in July 2017 FDA 2017. The mechanism is hypothesised to be NAD redox support in sickled erythrocytes. This is a prescription use; not what the catalogue's typical reader is doing with the powder, but it is the cleanest evidence of a real systemic effect at a defined dose.
protocol
The trial-supported regimens, by indication:
- Post-infectious IBS-D with documented hyperpermeability: 5 g three times daily (15 g/day) for 8 weeks Zhou et al. 2019.
- Endurance athletes for exercise-induced gut leak: 0.25–0.9 g/kg taken 1–2 h pre-event (~17–60 g for a 70-kg athlete); 7 days of pre-loading at 0.9 g/kg/fat-free-mass also shown effective Pugh et al. 2017 Zuhl et al. 2014.
- Endurance-athlete URTI prophylaxis: 5 g immediately post-race and again at 2 h Castell et al. 1996.
- Severe burns ≥20% BSA in hospital: 0.3–0.5 g/kg/day enteral for 10–15 days Singer et al. 2023. Inpatient only.
- Sickle-cell crisis prophylaxis: 0.3 g/kg twice daily as the prescription product Endari Niihara et al. 2018.
The common consumer protocol — 5 g once daily, indefinitely, with no underlying stressor or barrier injury — has no trial backing. It is at best the lower bound of doses that have done anything in any trial.
contraindications
The safety profile is favourable at consumer doses: Garlick's safety assessment found no adverse effects at up to 0.65 g/kg/day acute in healthy adults Garlick 2001; chronic use at 5–30 g/day has not produced consistent laboratory abnormalities Cruzat et al. 2018. The exceptions are not academic:
- Critical illness with multi-organ failure or renal failure. Early high-dose IV+enteral glutamine increased mortality in REDOXS Heyland et al. 2013. Not a consumer issue, but the supplement should be stopped on ICU admission.
- Liver failure / cirrhosis. Glutamine is metabolised to glutamate and ammonia; a compromised urea cycle plus high glutamine load can worsen hepatic encephalopathy.
- Reye-syndrome-like states / inborn errors of urea cycle. Same ammonia-handling concern.
- Bipolar disorder, seizure disorders. Theoretical (glutamine → glutamate, an excitatory neurotransmitter); not well-quantified, but reported in case literature.
misconceptions
"Leaky gut → take glutamine" is the supplement-influencer pitch and is mostly wrong as framed. The pooled meta-analysis is negative at consumer doses; the positive trials require a documented permeability defect (post-infectious IBS, exercise-induced) and either much higher acute doses or specific timing Singleton et al. 2024. Daily 5 g for a healthy person with normal digestion has no demonstrated effect on barrier function.
"More glutamine = more muscle." The bodybuilding-magazine claim. Healthy adults already synthesize 10–25 g/day endogenously; exogenous glutamine does not raise muscle protein synthesis or improve strength/hypertrophy in any meta-analysed RCT Ramezani Ahmadi et al. 2019 Gleeson 2008. The soreness signal is modest; the strength/mass signal is null.
"Plasma glutamine drops after exercise, so we need to top it up." The "glutamine hypothesis" of post-exercise immunodepression has not aged well — the in-vitro concentrations at which lymphocyte function is impaired sit far below the post-exercise nadir, and most randomised trials of glutamine for immune endpoints in trained athletes are null. Castell's URTI signal remains real for the prolonged-exercise post-event window specifically, not for chronic supplementation in general Cruzat et al. 2018.
"It's an amino acid, so it's just safer protein." True at supplement doses; false at ICU doses. REDOXS is a real harm signal in a specific population, not a hypothetical Heyland et al. 2013.
failure-modes
- Wrong population. Healthy adult with no gut symptoms and no endurance training takes 5 g/day and notices nothing. The substrate is already abundant; adding more does nothing.
- Wrong dose for the gut claim. The barrier-effect doses are 15 g/day (IBS-D), 17–60 g acute (endurance), 30+ g/day (the pooled meta-analysis subgroup). The default 5 g/day is below the floor for the barrier indication.
- Wrong timing for the URTI claim. Immediate post-event matters; chronic daily background does not appear to.
- Treating glutamine as a substitute for actually addressing the cause. The post-infectious IBS-D trial worked because the population had a defined barrier lesion; chronic SIBO, food intolerance, or undiagnosed celiac is not fixed by glutamine.
practicalities
Free-form L-glutamine powder, ~$15–30 for 500 g (90 servings at 5 g, 30 days at 15 g). Unflavoured, slightly sweet, water-soluble. Stable at room temperature. Pharmacopeial purity is generally good (NSF-certified products exist for athletes). The prescription form (Endari) is dramatically more expensive but identical molecule.
Mild GI side effects (bloating, loose stool) reported above ~10 g/dose; splitting larger daily totals across doses helps. Should be taken with water, not with high-carbohydrate meals that compete for splanchnic absorption.
stakes
For the supplement-aisle reader chasing "gut health" — modest stakes either way. The default 5 g/day is unlikely to harm and unlikely to help. The deeper cost is opportunity: time and money spent on a low-yield supplement instead of fibre, fermented foods, sleep, or a workup for actual GI symptoms (celiac, SIBO, IBD, food intolerance) — interventions with real effect sizes.
For the endurance athlete with race-day GI distress — a real, well-documented problem cluster (cramping, urgency, post-race URTI) that this supplement can partially address. Skipping it is a missed cheap intervention.
payoff
Realistic payoffs by population:
- Post-infectious IBS-D with leaky barrier: ~80% chance of a meaningful symptom reduction over 8 weeks (Zhou trial primary endpoint) Zhou et al. 2019.
- Endurance athlete with race-day GI distress: smaller, less consistent reduction in symptoms; clearer reduction in laboratory permeability markers; modest reduction in post-race URTI.
- T2D postprandial control: ~10% reduction in postprandial glucose AUC when 30 g taken with the meal Samocha-Bonet et al. 2011. Real but small in absolute terms.
- Healthy adult chasing "gut health" or muscle: no detectable payoff.
audience
The candidate audiences are narrower than the marketing implies: post-infectious IBS-D (sub-population of IBS-D, themselves ~5% of adults); endurance athletes during heavy training; severe-burn inpatients (hospital-only); sickle-cell patients (prescription); type-2 diabetics seeking adjunct postprandial control. The mass-market audience implied by supplement shelves — "anyone with bloating," "anyone training" — is the wrong audience.
The credibility range
Optimist case
Glutamine is the primary fuel for the cells whose dysfunction we now think drives many of modern medicine's chronic conditions — enterocytes (gut barrier → systemic inflammation), immune cells (susceptibility to infection), L-cells (incretin response → glucose control). Mechanism is rigorously characterised in vitro and in vivo; the relevant tissues extract it on first pass, so oral dosing reaches them. The cleanest human trial — Zhou's post-infectious IBS-D study — shows a dramatic effect size (~80% responder rate vs 6%) in a well-defined phenotype. The exercise-permeability literature is consistent across multiple labs. The FDA approved L-glutamine for sickle cell on the basis of a phase-3 trial. The harm signals are confined to one specific ICU population on dramatically higher doses; consumer dosing has a clean safety record over decades.
Skeptic case
The 2024 meta-analysis is null at the population level; only a subgroup of high-dose short-duration trials moves the needle. Castell's 1996 URTI result has not been cleanly replicated in three decades. The 2019 athletic-performance meta-analysis is fully null for the consumer outcomes (strength, hypertrophy, body composition, chronic immune endpoints). The original "glutamine hypothesis" of post-exercise immunodepression is mechanistically incoherent at the relevant plasma concentrations. The supplement industry promotes a "leaky-gut → glutamine" pipeline that is unsupported in healthy adults. The IBS-D trial is one centre, one 8-week endpoint, in a heavily selected subgroup, and has not been independently replicated. The ICU literature shows real harm in the wrong population, which forces caution about the broader "more must be better" framing. And glutamine is cheap precisely because it is endogenously synthesized in 10–25 g/day amounts already — exogenous dosing is meaningful only when this synthesis is overrun.
Author's call
Glutamine is a real, narrow intervention with three or four legitimate use cases (post-infectious IBS-D with documented barrier dysfunction; endurance-athlete gut leak and post-race immune dip; severe burns under medical supervision; sickle-cell crisis prophylaxis as a prescription drug) and a much larger zone of consumer mythology around generic "gut healing" and "muscle recovery". The article's job is to draw that line cleanly: name the populations where the trial dose works, name the dose, name the duration, and otherwise call the daily-5-g habit what it is — low-cost, low-yield, generally harmless. Evidence rating sits at 3 — multiple solid mechanism studies and one strong RCT (Zhou) for the gut-barrier use, plus a Phase-3 trial in sickle cell, but the broader consumer claims do not have RCT support and the meta-analyses are mostly null. Controversy ~2 — the field does not really disagree about the underlying science; the disagreement is in marketing, not in mechanism.
Stakeholder + incentive map
- Supplement industry. Glutamine is a high-margin bulk amino acid (cheap to produce, easy to market as "recovery" or "gut health"). The "leaky gut" narrative is a profitable consumer pitch even where the evidence does not support it.
- Sports-nutrition publications. Long-running affinity for the Castell hypothesis; the muscle-recovery claim survives in popular print well after RCTs nulled it.
- Critical-care community. Largely retreated from routine glutamine after REDOXS; ESPEN's 2023 guideline reflects the chastened view.
- Gastroenterology. Cautiously interested for post-infectious IBS-D after Zhou 2019; few clinicians use it as first-line yet.
- Emmaus Medical / sickle-cell community. Endari is FDA-approved; usage is real but not universal because uptake of L-glutamine has been less than hydroxyurea and newer agents.
Population variability
- Documented hyperpermeability matters. Zhou's positive trial required elevated lactulose/mannitol at baseline; subgroups with normal permeability did not respond — the substrate ceiling matters.
- Training load matters. Effects on gut permeability are clearest under heavy endurance load (≥60 min, often in heat). Casual exercisers show no permeability defect to correct.
- Catabolic stress matters. Endogenous synthesis covers needs in healthy adults; trauma, sepsis, burns, prolonged starvation, and intense exercise can outrun synthesis. The supplement is "essential" only in those windows.
- Renal function matters. Renal failure was the harm-modifier in REDOXS; glutamine clearance is reduced and ammonia load rises.
- Diabetes/T2D. The GLP-1 response and postprandial glucose effect are larger in T2D than in lean controls — likely because GLP-1 reserve is higher in the unstimulated state in T2D.
Knowledge gaps
- No independent replication of the Zhou 2019 IBS-D trial. Until it lands, the 5-g-TID-for-8-weeks protocol rests on a single study.
- No long-term safety data for chronic high-dose (15–30 g/day) consumer use beyond ~2 months.
- The exercise-permeability → infection-rate chain is plausible but the direct evidence linking glutamine's permeability effect to clinical outcomes (sick days, performance) is thin.
- The interaction between glutamine and modern incretin/GLP-1 agonist drugs in T2D is unstudied; the GLP-1 axis is now saturated by drug effect in many of these patients.
- No head-to-head against bovine colostrum or zinc-carnosine for exercise-induced gut leak.
Narrowing versus the brief. The topic brief named four consequences (gut barrier, immune function, muscle recovery, glucose handling) and the article covers all four — but three of them land on a negative or sharply qualified verdict at consumer doses, which is the honest read of the evidence. The dek and tagline frame this as a "decide" entry rather than a "do" because the population-level pitches the supplement industry runs do not hold up; the entry's job is to name the narrow populations where the trial dose works and warn off the rest.
Scoring choices worth flagging.
health_short_termat 2 is a deliberately weighted average. For the post-infection IBS-D subgroup in Zhou 2019 the effect would warrant a 4; for the rest of the catalogue's reader base it is a 0. The 2 reflects the honest expectation across "the typical reader of this entry," not a flat average across all uses.longevityscored 0 despite the sickle-cell and burn data, because those are prescription/hospital uses and not what the catalogue reader is doing with the powder.energy,focus,sleep,moodall 0 — none of these have RCT support and the dossier is silent on them; resisted the urge to score 1 on energy "because amino acids".evidenceat 3 reflects the split: one strong RCT (Zhou 2019) plus solid mechanism and a Phase 3 sickle-cell trial, against a null pooled meta-analysis and a null athletic-performance meta. Could argue for 2; landed at 3 because Zhou is genuinely high-quality and the FDA-approval anchor is real.contraindicationstoken: onlykidney-diseasefrom the closed vocabulary fit cleanly. The liver-failure and seizure cautions are noted in the article body but don't have a matching token.
Excluded on purpose.
- Detailed sickle-cell protocol — that is a prescription drug use (Endari), not what consumers are buying glutamine powder for. Cited as anchor for "real systemic effects exist at defined doses" and left there.
- Burn-unit detail — same reasoning; included as evidence anchor, not as a consumer protocol.
- The full critical-care literature beyond Heyland 2013 (REDOXS) — RE-ENERGIZE (Heyland 2022) is in the research dossier but not the article, since the burn story is in-hospital only and adding a second critical-care trial to a consumer-facing article muddied the read.
- HMB, BCAAs, and other amino-acid recovery alternatives — adjacent entries, flagged as future links rather than handled here.
Future link candidates. A dedicated post-infectious IBS entry (currently absent) would carry the Zhou 2019 protocol with more clinical detail and is the right home for that material long-term; this entry's protocol callout is the supplement-side projection of it. A runner's gut / exercise-induced gut permeability entry would consolidate Pugh/Zuhl and let this entry just cross-link. A creatine entry, an FODMAP-elimination entry, a celiac screening entry — all named in out-of-scope, all candidates for cross-links once they exist.
Hard decision during the write. Whether to lead the dek with relief/debunking voice or with the narrow positive case. Picked the relief framing because the dominant reader is the supplement-aisle shopper, not the IBS patient — the article serves both, but the hook earns its read by surprising the larger audience. Dream narrative was optional at this score (~10); written anyway to anchor the tagline's "marketed for everyone, works for almost no one" lever.
Rating difficulty. applicability was the hardest call. The legitimate aggregate audience (post-infection IBS-D + endurance athletes + T2D adjunct + sickle cell + burns) is wider than any one of them, but each remains a small slice. Landed at 2 ("meaningful slice, ~5–15%") rather than 3 because no single one of these populations reaches a quarter of adults.
L-Glutamine for Gut and Recovery
A pot of powder runs $15 to $30 and lasts a month or two even at trial doses. Cheap to try.
A scoop in water once or twice a day. Tasteless, no timing rules to learn for general use.
One solid trial in a specific kind of post-infection IBS, decent mechanism work for the gut lining, and a clean track record for severe burns and sickle-cell pain. Most other claims (muscle, immunity, general "leaky gut") don't hold up when tested.
If your gut barrier is genuinely leaky after a stomach infection, or you finish long runs with cramps and the sniffles, this can take the edge off within weeks. For most people, you won't feel a thing.